210890-90-7

Usage

Uses

Used in Pharmaceutical Research:
(4E)-4-[(2E)-2-7-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-8-hydroxyquinolin-2(1H)-ylideneethylidene]-2-hydroxycyclohexa-2,5-dien-1-one is used as a potential pharmaceutical candidate for various applications due to its complex structure and multiple functional groups. Its unique biological properties may allow for the development of new drugs and therapies.
Used in Medical Research:
In the field of medical research, (4E)-4-[(2E)-2-7-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-8-hydroxyquinolin-2(1H)-ylideneethylidene]-2-hydroxycyclohexa-2,5-dien-1-one is utilized for exploring its potential interactions in biological systems. Its diverse properties may contribute to a better understanding of various diseases and conditions, potentially leading to the discovery of novel treatments and interventions.

Upstream product

• 67727-64-4 3,4-diacetoxybenzaldehyde 
• 210891-02-4 4-[(E)-2-(8-Hydroxy-2-methyl-quinolin-7-yl)-vinyl]-benzene-1,2-diol 

Relevant academic research and scientific papers

Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells

On the basis of the fact that several polynucleotidyl transferases, related to HIV integrase, contain in their active site two divalent metal cations, separated by ca. 4 ?, new potential HIV integrase inhibitors were designed, in which a quinoline substructure is linked to an aryl nucleus possessing various hydroxy substitution patterns, by means of an ethylenic spacer. Although the most active compounds contain the catechol structure, this group is not essential for the activity, since compound 21 that lacks such a moiety is a potent drug, implicating the presence of a different pharmacophore. The most promising styrylquinolines thus synthesized inhibit HIV-1 integrase in vitro at micromolar or submicromolar concentrations and block HIV replication in CEM cells, with no significant cellular toxicity in a 5-day period assay. These inhibitors are active against integrase core domain-mediated disintegration, suggesting that fragment 50-212 is their actual target. These new styrylquinolines may provide lead compounds for the development of novel antiretroviral agents for AIDS therapeutics, based upon inhibition of HIV integrase. They might also be used in the elucidation of the mechanism of inhibition of this enzyme; e.g., they could serve as candidates for cocrystallization studies with HIV integrase.